CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

triheptanoin

Last Updated: April 16, 2021
Result type: Reports
Project Number: SR0684-000
Product Line: Reimbursement Review

Generic Name: triheptanoin

Brand Name: Dojolvi

Manufacturer: Ultragenyx Canada Inc

Therapeutic Area: Long-chain fatty acid oxidation disorders

Indications: Dojolvi (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). ​

Manufacturer Requested Reimbursement Criteria1: Ultragenyx is requesting triheptanoin be reimbursed for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openFebruary 26, 2021
Call for patient/clinician input closedApril 23, 2021
Submission receivedMarch 31, 2021
Submission acceptedApril 15, 2021
Review initiatedApril 16, 2021
Draft CADTH review report(s) provided to sponsor for commentJune 30, 2021
Deadline for sponsors commentsJuly 12, 2021
CADTH responses on draft review report(s) provided to sponsorAugust 06, 2021
Expert committee meeting (initial)August 18, 2021
Draft recommendation issued to sponsorAugust 30, 2021
To
September 01, 2021
Draft recommendation posted for stakeholder feedback-
Submit Feedback